Skip to Navigation Skip to Search Skip to Content
Search All Centers

Isatuximab-irfc (Sarclisa) As a Multiple Myeloma Treatment

Read Transcript
View next

Published on September 9, 2020

What is isatuximab-irfc (Sarclisa) and Can It Be Used To Treat Myeloma?

How is Sarclisa used to treat multiple myeloma and does it have side effects? What myeloma patients could it be right for? Watch as host and myeloma patient Cindy Chmielewski and Dr. Natalie S. Callander from the University of Wisconsin School of Medicine and Public Health and Dr. Cesar Rodriguez of Wake Forest Baptist Health discuss this drug as a treatment for myeloma.

Featuring

Transcript | Isatuximab-irfc (Sarclisa) As a Multiple Myeloma Treatment

What Should Myeloma Patients Know About isatuximab-irfc (Sarclisa)?

Cindy Chmielewski: 

Anything we should know about the new drug isatuximab (Sarclisa), any unusual side effects 

Dr. Callander: 

No. 

Cindy Chmielewski: 

Any heads up? 

Dr. Callander: 

Yeah, so as far as we know about isatuximab, so this was recently FDA approved only right now in combination with pomalidomide (Pomalyst) and dexamethasone (Decadron), and that was based on a trial that was done largely outside of the US where it was compared with pomalidomide and dexamethasone and doubled the progression free survival, that means how long your myeloma takes to get active again. The side effects that we're seeing are similar to what's been noticed with daratumumab (Darzalex), a little bit lower in terms of infusion related side effects in the sort of 30% range rather than close to 50%, which was in some of the original daratumumab trials. The infusions are a little bit faster compared to daratumumab. The dosing ends up being a little bit different. There is that sort of initial weekly infusions and then it becomes bi-weekly, but it stays bi-weekly, and that's a little bit different than daratumumab. The other difference that we know is that it targets CD38, that's a protein that's found on myeloma cells but some other hematologic, other blood cells as well. 

The actual part of this protein that it binds to is somewhat different than daratumumab. I think Dr. Rodriguez made a comment, sometimes you sort of need some experience with a drug once it gets out there to see if there's something different with it. I think right now we don't have a lot of experience yet with isatuximab to know if there's something that will emerge that seems different, but many things do seem similar to daratumumab. 

Dr. Rodriguez: 

There has not been a head to head comparison between the two drugs to see which one is better, if one is better than the other and I don't think we're going to have that information anytime soon but it is something to keep in mind that if you had a reaction to daratumumab and you cannot receive daratumumab, you could be treated with isatuximab and not necessarily experience the same reactions. But if for some reason you have progressed on daratumumab and you are resistant to daratumumab drug, then isatuximab is not going to be the ground breaker that's going to come and help. If you're resistant to one you're resistant to both basically, but you're not necessarily going to be allergic to both if you're allergic to one. 

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.


Recommended Programs:

View next